Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

Beyond phage display: non-traditional applications of the filamentous bacteriophage as a vaccine carrier, therapeutic biologic, and bioconjugation scaffold.

Henry KA, Arbabi-Ghahroudi M, Scott JK.

Front Microbiol. 2015 Aug 4;6:755. doi: 10.3389/fmicb.2015.00755. eCollection 2015. Review.

2.

Antigenic cooperation among intrahost HCV variants organized into a complex network of cross-immunoreactivity.

Skums P, Bunimovich L, Khudyakov Y.

Proc Natl Acad Sci U S A. 2015 May 26;112(21):6653-8. doi: 10.1073/pnas.1422942112. Epub 2015 May 4.

3.

Bacteriophages and their applications in the diagnosis and treatment of hepatitis B virus infection.

Bakhshinejad B, Sadeghizadeh M.

World J Gastroenterol. 2014 Sep 7;20(33):11671-83. doi: 10.3748/wjg.v20.i33.11671. Review.

4.

Hepatitis C virus hypervariable region 1 variants presented on hepatitis B virus capsid-like particles induce cross-neutralizing antibodies.

Lange M, Fiedler M, Bankwitz D, Osburn W, Viazov S, Brovko O, Zekri AR, Khudyakov Y, Nassal M, Pumpens P, Pietschmann T, Timm J, Roggendorf M, Walker A.

PLoS One. 2014 Jul 11;9(7):e102235. doi: 10.1371/journal.pone.0102235. eCollection 2014.

5.

GB Virus C/Hepatitis G Virus Envelope Glycoprotein E2: Computational Molecular Features and Immunoinformatics Study.

Ranjbar MM, Ghorban K, Alavian SM, Keyvani H, Dadmanesh M, Roayaei Ardakany A, Motedayen MH, Sazmand A.

Hepat Mon. 2013 Dec 30;13(12):e15342. doi: 10.5812/hepatmon.15342. Review.

6.
7.

Apoptotic effects of a chimeric plant virus carrying a mimotope of the hepatitis C virus hypervariable region 1: role of caspases and endoplasmic reticulum-stress.

Piazzolla G, Nuzzaci M, Vitti A, Napoli N, Schiavone M, Piazzolla P, Antonaci S, Tortorella C.

J Clin Immunol. 2012 Aug;32(4):866-76. doi: 10.1007/s10875-012-9676-1. Epub 2012 Mar 6.

8.

Vaccination with dendritic cells pulsed with hepatitis C pseudo particles induces specific immune responses in mice.

Weigand K, Voigt F, Encke J, Hoyler B, Stremmel W, Eisenbach C.

World J Gastroenterol. 2012 Feb 28;18(8):785-93. doi: 10.3748/wjg.v18.i8.785.

9.

Hepatitis C virus antigenic convergence.

Campo DS, Dimitrova Z, Yokosawa J, Hoang D, Perez NO, Ramachandran S, Khudyakov Y.

Sci Rep. 2012;2:267. doi: 10.1038/srep00267. Epub 2012 Feb 15.

10.

Neutralizing antibody response to hepatitis C virus.

Wang Y, Keck ZY, Foung SK.

Viruses. 2011 Nov;3(11):2127-45. doi: 10.3390/v3112127. Epub 2011 Nov 2. Review.

11.

Characterization of hepatitis C Virus genotype 3a hypervariable region 1 in patients achieved rapid virological response to alpha interferon and ribavirin combination therapy.

Akram M, Idrees M, Hussain A, Afzal S, Ilyas M, Zafar S, Aftab M, Badar S, Khubaib B.

Virol J. 2011 May 23;8:253. doi: 10.1186/1743-422X-8-253.

12.

Applying bioinformatics for antibody epitope prediction using affinity-selected mimotopes - relevance for vaccine design.

Denisova GF, Denisov DA, Bramson JL.

Immunome Res. 2010 Nov 3;6 Suppl 2:S6. doi: 10.1186/1745-7580-6-S2-S6.

13.

Evaluation of cross-reactive antibody response to HVR1 in chronic hepatitis C.

Xiu BS, Feng XY, He J, Wang GH, Zhang XY, Zhang HQ, Song XG, Chen K, Ling SG, Zhu CX, Wei L, Rao HY.

World J Gastroenterol. 2010 Sep 21;16(35):4460-6.

14.

Hepatitis C virus (HCV) infection may elicit neutralizing antibodies targeting epitopes conserved in all viral genotypes.

Mancini N, Diotti RA, Perotti M, Sautto G, Clementi N, Nitti G, Patel AH, Ball JK, Clementi M, Burioni R.

PLoS One. 2009 Dec 11;4(12):e8254. doi: 10.1371/journal.pone.0008254.

15.

Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants.

Catanese MT, Ansuini H, Graziani R, Huby T, Moreau M, Ball JK, Paonessa G, Rice CM, Cortese R, Vitelli A, Nicosia A.

J Virol. 2010 Jan;84(1):34-43. doi: 10.1128/JVI.02199-08. Epub .

16.

Purification of polyclonal anti-conformational antibodies for use in affinity selection from random peptide phage display libraries: a study using the hydatid vaccine EG95.

Read AJ, Gauci CG, Lightowlers MW.

J Chromatogr B Analyt Technol Biomed Life Sci. 2009 May 15;877(14-15):1516-22. doi: 10.1016/j.jchromb.2009.03.036. Epub 2009 Mar 28.

17.

Induction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2 and nonstructural proteins 3, 4, and 5.

Lin Y, Kwon T, Polo J, Zhu YF, Coates S, Crawford K, Dong C, Wininger M, Hall J, Selby M, Coit D, Medina-Selby A, McCoin C, Ng P, Drane D, Chien D, Han J, Vajdy M, Houghton M.

J Virol. 2008 Aug;82(15):7492-503. doi: 10.1128/JVI.02743-07. Epub 2008 May 28.

18.

High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein.

Catanese MT, Graziani R, von Hahn T, Moreau M, Huby T, Paonessa G, Santini C, Luzzago A, Rice CM, Cortese R, Vitelli A, Nicosia A.

J Virol. 2007 Aug;81(15):8063-71. Epub 2007 May 16.

19.

Structure of a high-affinity "mimotope" peptide bound to HIV-1-neutralizing antibody b12 explains its inability to elicit gp120 cross-reactive antibodies.

Saphire EO, Montero M, Menendez A, van Houten NE, Irving MB, Pantophlet R, Zwick MB, Parren PW, Burton DR, Scott JK, Wilson IA.

J Mol Biol. 2007 Jun 8;369(3):696-709. Epub 2007 Jan 27.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk